Filtered By:
Cancer: Sarcomas
This page shows you your search results in order of relevance. This is page number 8.
Order by Relevance | Date
Total 120 results found since Jan 2013.
Acroangiodermatitis presenting as unilateral hypertrophic verrucous plaques
Dermatol Online J. 2022 Mar 15;28(2). doi: 10.5070/D328257400.ABSTRACTAcroangiodermatitis (AAD)[KL1] is a rare vasoproliferative disorder often involving the extremities that has been classified into two variants. Mali-type AAD is more common and associated with chronic venous stasis. Stewart-Bluefarb syndrome[KL2], the other variant, is associated with underlying arteriovenous abnormalities. Mali-type AAD is a relatively benign diagnosis but it may mimic more harmful etiologies such as Kaposi sarcoma both clinically and histologically. A 67-year-old woman with a history of varicose veins, deep vein thrombosis, stroke, and...
Source: Dermatol Online J - June 7, 2022 Category: Dermatology Authors: Kyle Lauck Quoc-Bao Nguyen Natasha Klimas Megan Rogge Source Type: research
A case report of an ischaemic stroke, caused by a primary cardiac intimal sarcoma
We present a case of intimal sarcoma identified without any cardiac s...
Source: BMC Cardiovascular Disorders - February 1, 2023 Category: Cardiology Authors: Joshua Lloyd, Navinee Gilliat, Graeme Porter and Francesco Pirone Tags: Case Report Source Type: research
A case of acute ischemic stroke caused by doxorubicin-induced cardiomyopathy in a patient with synovial sarcoma
Source: Acta Neurologica Belgica - March 30, 2023 Category: Neurology Source Type: research
LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases —a phase II study
ConclusionsPanitumumab and FOLFIRI as perioperative therapy for resectable CLM result in a radiological objective response rate in 65.7% of patients with a manageable grade 3 diarrhea rate of 14.3%. Median PFS was 13.2 months, and the 24-month OS rate was 73.3%. These data are insufficient to widen the indication of panitumumab from the unresectable setting to the setting of resectable CLM.
Source: Frontiers in Oncology - August 9, 2023 Category: Cancer & Oncology Source Type: research
